Hikal Limited

Equities

HIKAL

INE475B01022

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:47 2024-04-25 am EDT 5-day change 1st Jan Change
308.7 INR -0.98% Intraday chart for Hikal Limited +1.83% +1.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million. CI
Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors CI
Hikal Limited Announces the Demise of Board Member, Ranjit Gobindram Shahani CI
ICRA Affirms A+ Rating on Hikal; Outlook Stable MT
Hikal Limited Announces Appointment of Dharmesh Panchal as the Chief Technology Officer CI
Transcript : Hikal Limited, Q3 2024 Earnings Call, Feb 09, 2024
Hikal Limited Declares Interim Dividend for the Financial Year 2023-2024, Payable on or Before March 9, 2024 CI
Hikal Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Hikal Limited Announces Resignation of B. N. Kalyani as Director CI
Hikal Targets Acquisition of 26% Stake in Renewable Power Company FPEL Ujwal MT
Transcript : Hikal Limited, Q2 2024 Earnings Call, Nov 02, 2023
Hikal Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Hikal Limited agreed to acquire 26% stake in Fpel Ujwal Private Limited for INR 41.2 million. CI
Hikal Limited Announces Executive Appointments CI
Hikal Limited Approves the Appointment of Berjis M Desai and V. Ramachandra Kaundinya as an Independent Director CI
Hikal Limited Approves the Declaration of Final Dividend for the Financial Year 2022-23 CI
Transcript : Hikal Limited, Q1 2024 Earnings Call, Aug 08, 2023
Hikal Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Hikal Limited Receives Communication from the Gujarat Pollution Control Board CI
Hikal Books Higher Consolidated Profit in Fiscal Q4 MT
INDIA STOCKS-Indian shares rise to five-month high on improved global cues RE
Transcript : Hikal Limited, Q4 2023 Earnings Call, May 29, 2023
Hikal Limited Announces Recommendation of Final Dividend for the Financial Year 2022-23 CI
Hikal Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Hikal Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Chart Hikal Limited
More charts
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
311.8 INR
Average target price
330 INR
Spread / Average Target
+5.85%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HIKAL Stock
  4. News Hikal Limited
  5. Hikal Acquires Stake in Two Solar Power Firms